Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

AZ takes aim at BMS’ lead in neoadjuvant NSCLC

Blueprint cashes in on the past to build its future

Medical Devices and IVD Conference

Liver injuries prompt clinical hold on Sanofi BTK drug

Pfizer claims new $3.2bn COVID jab deal with US government

BioCryst Pharma

Biocryst_pharma_logo

Market Access/ News/ News

NICE backs BioCryst’s Orladeyo for hereditary angioedema

Phil Taylor BioCryst Pharma, HEOR, hereditary angioedema, NICE, Orladeyo, rare disease 0 Comment

BioCryst Pharma’s Orladeyo has been recommended by NICE as a treatment for the rare disease hereditary angioedema (HAE)

X

NICE backs BioCryst’s Orladeyo for hereditary angioedema

https://pharmaphorum.com/news/nice-backs-biocrysts-orladeyo-for-hereditary-angioedema/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Pfizer seeks to overturn three RSV vaccine patents held by GSK
Novartis will shed 7% of workforce in restructuring, say reports
Celebrations for ASMD community as EU clears Sanofi's Xenpozyme
Gilead tries again with twice-yearly HIV drug lenacapavir
Pfizer and Roivant launch autoimmune specialist Priovant

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com